• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Lilly launches trial for automated insulin delivery system

December 5, 2017 By Sarah Faulkner

Eli Lilly

Eli Lilly (NYSE:LLY) yesterday dosed the first patient in a trial of its automated insulin delivery system.

The system is a hybrid closed-loop platform that includes a connected insulin pump, a dosing algorithm and a continuous glucose monitor.

“This trial is a significant step forward for Lilly’s Connected Care program, moving the Connected Diabetes Ecosystem closer to hopefully becoming available to the millions of people with diabetes who need a simpler, more effective way to use insulin,” Marie Schiller, VP of the company’s connected care unit, said in prepared remarks.

The insulin-maker is developing two platforms for its Connected Diabetes Ecosystem – an automated insulin delivery system and an integrated insulin management system. The latter combines a connected insulin pen with glucose-sensing tech and software to create personalized insulin dose recommendations.

Both systems are in development and are slated to enter clinical trials for people with Type I and Type II diabetes within the coming months, Lilly reported.

Contingent upon FDA approval, Lilly expects that these technologies will reach the market in two to three years.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Eli Lilly & Co.

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS